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were quantified.  Results: Acute ICP, rCBF, and MABP did not 
differ between WT and MMP-9 –/– mice, while 7 days’ mor-
tality was lower in MMP-9 –/– mice (p = 0.03; 20 vs. 60%). 
MMP-9 –/– mice also exhibited better neurological recovery, 
less brain edema formation, and lower chronic ICP.  Conclu-
sions: The results of the current study suggest that MMP-9 
contributes to the development of early brain damage after 
SAH by promoting cerebral edema formation. Hence, MMP-
9 may represent a novel molecular target for the treatment 
of SAH.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Subarachnoid hemorrhage (SAH) is a subtype of hem-
orrhagic stroke with a particularly high mortality and 
morbidity  [1] . Among others, brain edema has been iden-
tified as a major independent risk factor for mortality and 
poor outcome after SAH  [2] . Posthemorrhagic brain 
edema is mostly vasogenic, i.e. it results from a dysfunc-
tion of the blood-brain barrier  [3] . As previously shown, 
blood-brain barrier dysfunction starts 6 h after experi-
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 Abstract 
 Background: Cerebral edema is an important risk factor for 
death and poor outcome following subarachnoid hemor-
rhage (SAH). However, underlying mechanisms are still poor-
ly understood. Matrix metalloproteinase (MMP)-9 is held re-
sponsible for the degradation of microvascular basal lami-
na proteins leading to blood-brain barrier dysfunction and, 
thus, formation of vasogenic cerebral edema. The current 
study was conducted to clarify the role of MMP-9 for the de-
velopment of cerebral edema and for functional outcome 
after SAH.  Methods: SAH was induced in FVB/N wild-type 
(WT) or MMP-9 knockout (MMP-9 –/– ) mice by endovascular 
puncture. Intracranial pressure (ICP), regional cerebral blood 
flow (rCBF), and mean arterial blood pressure (MABP) were 
continuously monitored up to 30 min after SAH. Mortality 
was quantified for 7 days after SAH. In an additional series 
neurological function and body weight were assessed for 3 
days after SAH. Subsequently, ICP and brain water content 
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mental SAH, peaks at 2 days, and correlates with the deg-
radation of collagen IV  [4] , a major component of the mi-
crovascular basal lamina which serves as an important 
component of the blood-brain barrier  [5] .
 Collagen IV, amongst other basal lamina proteins, can 
be degraded by matrix metalloproteinase-9 (MMP-9, 
type IV collagenase), a member of the MMP family of 
zinc-containing proteinases  [6] . MMPs play a pivotal role 
for the development and normal function of the brain 
and other organs by modulating cell-matrix interactions 
 [7] . Under pathological conditions, e.g. focal cerebral 
ischemia, MMP-9 expression is detectable in patients  [8] 
and in experimental animals  [9] , and is held responsible 
for the development of vasogenic cerebral edema  [10] . Re-
cent publications have demonstrated that MMP-9 is up-
regulated and activated after SAH  [11, 12] ; however, since 
highly specific pharmacological inhibitors are missing, 
the pathophysiological role of MMP-9 after SAH has not 
been clarified yet.
 The aim of the current study was therefore to clarify 
the role of MMP-9 for the development of cerebral edema 
and for functional outcome following SAH using MMP-9 
knockout mice.
 Methods 
 Thirty-five male and female MMP-9 knockout (MMP-9 –/– ) 
mice (body weight 20–25 g; Jackson Laboratory, Bar Harbor, Me., 
USA) and 40 age- and weight-matched FVB/N wild-type (WT) 
mice (Charles River, Sulzfeld, Germany) were used for the cur-
rent experiments. FVB/N mice were chosen as controls because 
MMP-9 –/– mice, originally generated by Vu et al.  [13] , were bred 
and back-crossed for more than 10 generations on this background.
 The genotype of MMP-9 –/– mice was confirmed by polymerase 
chain reaction. The following primers were used to amplify a 172-
bp mutant product (oIMP0158, 5  -CTG AAT GAA CTG CAG 
GAC GA-3  and oIMR0159, 5  -ATA CTT TCT CGG CAG GAG 
CA-3  ) or the 277-bp WT product (oIMR1760, 5  -GTG GGA CCA 
TCA TAA CAT CAC A-3  and oIMR1761, 5  -CTC GCG GCA 
AGT CTT CAG AGT A-3  ).
 Experimental animals were cared for prior to and at all stages 
of the experiments in compliance with institutional guidelines 
and approved by the Animal Care Committee of the District Gov-
ernment of Upper Bavaria (protocol number 221-2531-117/05 and 
66/08).
 Anesthesia, Monitoring, and Induction of SAH 
 Anesthesia was induced by intraperitoneal injection of mid-
azolam, fentanyl and medetomidin  [14] . Subsequently, animals 
were intubated and mechanically ventilated, and end-tidal pCO 2 
was measured by microcapnometry (CI240, Columbus Instru-
ments, Columbus, USA). After medial skin incision, dissection of 
the temporal muscle and drilling of a   1.5-mm burr hole, an in-
tracranial pressure (ICP) probe (Johnson & Johnson Medical 
Limited, Berkshire, UK) was positioned in the epidural space 
above the frontal cortex of the right hemisphere to monitor ICP 
prior and after induction of SAH. Regional cerebral blood flow 
(rCBF) was measured continuously with a flexible laser Doppler 
probe (rCBF; Perimed 4001 Master, Perimed, Järfälla, Sweden) 
being glued onto the skull above the territory of the left middle 
cerebral artery. Mean arterial blood pressure and blood gases 
were measured through a catheter placed in the left femoral ar-
tery. SAH was induced using the endovascular perforation model 
as previously described  [15] . Briefly, the common carotid artery 
was exposed and a 5-0 monofilament was introduced into the in-
ternal carotid artery via the left external carotid artery. The fila-
ment was advanced distally until a sudden sharp increase in ICP 
indicated SAH. Thereafter, the filament was immediately with-
drawn and the external carotid artery was ligated. At the end of 
posthemorrhagic monitoring probes were removed, the burr hole 
was closed with dental cement, and anesthesia was terminated by 
intraperitoneal injection of atipamezol, naloxon, and flumazenil 
 [14] . Mice were kept in an incubator at an ambient temperature of 
33  °  C for 24 h.
 Experimental Groups 
 One single investigator performed all surgeries (S.F.). All indi-
viduals involved in the current study were blinded towards the 
genotype of the animals until completion of data analysis. Ani-
mals were allocated to groups using block randomization.
 In the first experimental series multimodal monitoring (ICP, 
rCBF, and mean arterial blood pressure) was carried out for 30 
min after SAH in WT and MMP-9 –/– mice (n = 7 in each group). 
Subsequently, arterial blood samples were analyzed and animals 
were sacrificed.
 In the second experimental series multimodal monitoring was 
also carried out. Thereafter, WT and MMP-9 –/– mice (n = 10 in 
each group) were observed for a postoperative period of 7 days to 
determine long-term mortality.
 In the third experimental series – after multimodal monitor-
ing – neurological deficits, body weight, and mortality was quan-
tified during an observation period of 3 days in MMP-9 –/– and 
WT mice. After 3 days, ICP was measured again and brains were 
removed for quantification of brain water content. Animals that 
died after the operation were replaced until n = 12 animals in the 
MMP-9 –/– group and n = 11 animals in the WT group survived 
the 3 days’ observation period. For this purpose surgery had to be 
performed in n = 14 MMP-9 –/– mice and n = 19 WT mice. Due to 
technical reasons 3-day ICP and brain water content data are only 
available in n = 11 MMP-9 –/– animals. Brain water content was 
also measured in n = 4 naive WT and MMP-9 –/– mice (that did 
not undergo any invasive procedure) in order to obtain normal 
values.
 Neurological Function and Body Weight 
 The neurological function was assessed as previously de-
scribed using a global SAH score that particularly considers SAH-
specific neurological deficits  [16] . The best achievable total score 
was 1 point, the worst 19 points ( table 1 ). Body weight was assessed 
prior to SAH and daily for the 3 days thereafter and was expressed 
in percent of the preoperative value.
 To avoid bias caused by the occurring mortality, all func-
tional data were corrected for mortality as previously described 
 [16] .
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 Quantification of Chronic ICP and Brain Edema 
 Animals were re-anesthetized 3 days after SAH. The skin inci-
sion was reopened, the dental cement was removed, and the ICP 
microsensor was reinserted into the right frontal burr hole. ICP 
values were taken 5 min after readings stabilized. Subsequently, 
animals were sacrificed by cervical dislocation in deep anesthesia. 
Brains were removed from the skull and cerebellum, and olfac-
tory bulbs were truncated. Hemispheres were separated and their 
wet weight (WW) was assessed using a precision balance. There-
after, the hemispheres were dried for 24 h at 110  °  C and their dry 
weight (DW) was determined. Hemispheric water content (%) was 
calculated using the following formula: [(WW – DW)/WW]  ! 
100.
 Statistical Analysis 
 Statistical analysis was performed using the SigmaStat 3.11 
statistical software package (SPSS Science Inc., Chicago, Ill., 
USA) and STATISTICA 9.1 (mortality analysis; StatSoft, Ham-
burg, Germany). Data were analyzed with the Mann-Whitney 
rank sum test. For the comparison of repeated measurements 
the signed rank test was used. Mortality was compared with the 
Cox’ F test. Statistical significance of results was assumed at p  ! 
0.05. Data are presented as mean  8 SEM if not indicated other-
wise.
 Results 
 Physiological Parameters 
 There were no significant differences in physiological 
parameters between MMP-9 –/– and WT groups 30 min 
after SAH ( table 2 ).
 SAH resulted in an immediate increase of ICP from 7 
to 60–70 mm Hg (p  ! 0.001 vs. pre-SAH baseline) fol-
lowed by a decrease to a plateau of   25 mm Hg within 10 
min after SAH ( fig. 1 a). This plateau was maintained up 
to 30 min after SAH in all groups. There were no signifi-
cant differences between groups indicating comparable 
degrees of SAH in all experimental animals.
Table 1.  Neuroscore (global SAH score)
Item Points Best Worse
Consciousness spontaneous movements/animal explores (1)
spontaneous movements/animal walks in the cage (2)
spontaneous movements/animal walks on the point (3)
movements after mild tactile stimulus (4)
animal movements after vertical movements of the cage (5)
movements after intense tactile stimulus (6)
coma (7)
1 7
Righting reflex present (0)
absent (1) 0 1
Corneal reflex bilateral present (0)
unilateral present (1)
absent (2)
0 2
Ear twitch reflex bilateral present (0)
unilateral present (1)
absent (2)
0 2
Sensory deficits reaction to tail pinch present (0)
reaction to tail pinch absent (1) 0 1
Whisker movements present (0)
absent (1) 0 1
Motor function [26] no apparent deficit (0)
contralateral forelimb flexion (1)
lowered resistance to lateral push without circling (2)
circling if pulled by tail (3)
spontaneous circling (4)
no spontaneous activity (5)
0 5
Total 1 19
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 Induction of SAH additionally resulted in a sharp de-
cline of ipsilateral rCBF (p  ! 0.001 vs. baseline) by over 70% 
to   25–30% of baseline values followed by recovery to a 
plateau of   80% of baseline values after 10–15 min ( fig. 1 b). 
There were no significant differences between groups.
 Mortality 
 Mortality was assessed in all experimental groups, i.e. 
in animals sacrificed 3 or 7 days after SAH. Mortality 
within 24 h was 14% in MMP-9 –/– and 37% in WT mice 
in the first series (3 days survival) and 10% in MMP-9 –/– 
and 30% in WT mice in the second series (7 days’ sur-
vival), i.e. very consistent between groups. The same con-
sistency was observed after 3 days. In the 3 days’ observa-
tion series mortality was significantly (p = 0.03) lower in 
the MMP-9 –/– group (2/14; 14%) as compared to the WT 
group (8/19; 42%); in the 7 days’ survival group mortality 
was 20% in MMP-9 –/– and 40% in WT mice. This differ-
ence persisted and became even more evident at the end 
of the observation period 7 days after SAH. No addition-
al MMP-9 –/– mice died during this period of time (total 
7-day mortality: 20%; p = 0.03 vs. WT;  fig. 2 a) while 2 
more mice died in the WT group (total 7-day mortality: 
40%;  fig. 2 a). 
 Neurological Function and Body Weight 
 Animals of both mouse strains exhibited no neuro-
logical deficits prior to SAH. During the 3 days’ posthem-
orrhagic observation period, MMP-9 –/– mice had signifi-
cantly (p  ! 0.05) less neurological deficits as compared to 
WT mice ( fig. 2 b).
 Body weight was 87.4  8 1.3, 84.3  8 1.5, and 84.4  8 
3.1% of preoperative values on days 1, 2, and 3, respec-
tively, in the MMP-9 –/– group, and 86.7  8 1.0, 80.8  8 2.1, 
and 80.6  8 3.5% on days 1, 2, and 3 in the WT group. 
Although there was a tendency towards a less pronounced 
postoperative weight loss in MMP-9 –/– mice this differ-
ence did not reach statistical significance.
Table 2.  Physiological parameters 30 min after SAH in WT and 
MMP-9–/– mice
WT MMP-9–/–
pH 7.3180.09 7.3580.03
PaCO2, mm Hg 4385 3886
Lactate, mg/dl 0.880.2 0.980.1
MABP, mm Hg 64.6811.2 76.8813.1
D ata are expressed as mean 8 SD (n = 7 in each group). pH = 
Arterial pH; PaCO2 = arterial pCO2; MABP = mean arterial blood 
pressure.
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 Fig. 1. Time course of ICP ( a ) and ipsilateral rCBF ( b ) up to 30 min after SAH in WT (controls) and MMP-9 –/– 
mice. SAH resulted in an acute ICP elevation with a subsequent decline to a plateau phase in all groups. In ad-
dition, SAH resulted in an acute massive impairment of cerebral perfusion followed by a gradual rCBF recovery 
to   80% of baseline during the monitoring period. There were no differences between groups. 
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 ICP and Brain Edema 3 Days after SAH 
 MMP-9 null mice showed significantly (p  ! 0.05) low-
er ICP values (5.4  8 2.4 mm Hg) than WT mice (11.2  8 
2.4 mm Hg) 3 days after SAH ( fig. 3 ).
 There was no difference in brain water content be-
tween naive MMP-9 and WT mice. SAH resulted in a 
significant increase (p  ! 0.001) in brain water content on 
posthemorrhagic day 3. The brain water content of the 
ipsilateral hemisphere was significantly (p  ! 0.05) lower 
in MMP-9 –/– mice (78.7  8 0.3%) compared to WT mice 
(79.6  8 0.4%), whereas the brain water content of the 
contralateral hemisphere did not differ between groups 
(MMP-9 –/ : 79.1  8 0.2%; WT: 79.6  8 0.4%;  fig. 4 ).
 Discussion 
 In the current study we intended to evaluate the role 
of MMP-9 for the pathophysiology of SAH. Since high-
ly specific pharmacological inhibitors for MMP-9 are 
not available, we used MMP-9 –/– mice and showed that 
these animals had a significantly lower mortality, a bet-
ter functional outcome as well as less brain edema for-
mation and lower ICP 3 days after SAH as compared to 
WT mice. These findings suggest that MMP-9 is in-
volved in the development of brain edema following 
SAH.
 The endovascular perforation model in mice used in 
the current study resembles the high mortality observed 
in SAH patients  [1] quite well, i.e. most animals that did 
not survive the observation period died within the first 
7 days after SAH. An additional advantage of the mu-
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 Fig. 2. Kaplan-Meier curve displaying posthemorrhagic mortality ( a ) and time course of neurological deficits 
( b ). MMP-9 –/– mice exhibited a significantly lower postoperative mortality (p = 0.03; Cox’ F test) and lesser 
neurological deficits, reaching statistical significance (p  ! 0.05; rank sum test) on posthemorrhagic day 2 com-
pared to WT mice. 
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 Fig. 3. Chronic ICP in animals subjected to SAH are displayed. 
MMP-9 –/– mice exhibited lower ICP values (p  ! 0.05; rank sum 
test) compared to WT mice 3 days after SAH. 
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rine SAH model is the possibility to use genetically en-
gineered animals for the study of SAH. In the specific 
case of MMP-9 the use of knockout mice allowed us to 
investigate its pathophysiological role after SAH with 
high specificity and selectivity. The experimental setup 
that we use includes multimodal monitoring and is 
highly standardized  [15, 16] . Epidural ICP measure-
ment, in particular, verifies the extent of SAH  [15] and 
was used in the current study in addition to rCBF mea-
surement to prove comparable degrees of SAH in both 
study groups.
 MMP-9 expression/activity has recently been charac-
terized after SAH by Sehba et al.  [11] . MMP-9 expression 
was increased by immunohistochemistry and staining 
was distributed segmentally along the microvasculature. 
Expression peaked at 6 h and recovered at 48 h after SAH. 
This is supported by results from Guo et al.  [12] , who de-
scribed an early significant increase of MMP-9 activity 
from 12 to 72 h after SAH peaking at 24 h. Accordingly, 
this increase of MMP-9 activity seems to take place with-
in the same 24- to 48-hour time frame as the degradation 
of microvascular collagen IV, a major MMP-9 target mol-
ecule, and the subsequent disruption of the blood-brain 
barrier  [4] . These findings suggest that SAH-induced ac-
tivation of MMP-9 contributes to the formation of post-
hemorrhagic cerebral edema by cleavage of microvascu-
lar protein components.
 Cerebral edema was identified as one of the major in-
dependent risk factors for death and poor outcome after 
SAH  [2] and, therefore, represents a key target for the 
development of novel therapeutic options. Despite the 
known fact that cerebral edema after SAH is, particu-
larly in the first days, predominantly of vasogenic origin 
 [3, 4, 17] , the mechanisms of the formation of posthemor-
rhagic brain edema are still not well understood. MMP-9 
that is regulated by a complex cascade involving plasmin, 
other MMPs (e.g. MMP-3, membrane type 1-MMP), the 
MMP inducer protein EMMPRIN and the tissue inhibi-
tors of MMPs  [18] is involved in brain edema formation 
after ischemic and hemorrhagic stroke  [19, 20] , as well as 
after traumatic brain injury  [21] . The major mechanisms 
postulated are the cleavage of extracellular matrix pro-
teins including collagen IV, laminin, and fibronectin  [22, 
23] , and the disruption of tight junction proteins like oc-
cludin  [24] leading to increased blood-brain barrier leak-
age and formation of vasogenic cerebral edema  [9, 25] . 
However, MMP-9 might also be involved in the develop-
ment of cytotoxic cerebral edema  [12] .
 The role of MMP-9 for the formation of cerebral ede-
ma after SAH, however, had not been addressed so far. 
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 Fig. 4. Brain water content of the ipsilat-
eral and the contralateral hemisphere in 
animals subjected to SAH and naive ani-
mals is displayed. MMP-9 –/– mice exhib-
ited a lesser increase (p  ! 0.05; rank sum 
test) of ipsilateral brain water content com-
pared to WT mice 3 days after SAH. 
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Our current data provide for the first time clear evidence 
that MMP-9 is involved in the formation of cerebral ede-
ma after SAH. The parallel temporal pattern of MMP-9 
activity shown by Guo et al.  [12] and of blood-brain bar-
rier damage/collagen IV reduction that we previously 
demonstrated  [4] as well as similar findings by Sehba et 
al.  [11] suggest that cleavage of collagen IV by MMP-9 
contributes to the formation of posthemorrhagic cerebral 
edema in the rodent brain.
 The potential effect of an MMP-9-targeted antiedema 
therapy can be guessed by the remarkably reduced mor-
tality and functional outcome in MMP-9-deficient mice 
that we found. This neuroprotective effect is best ex-
plained by the reduced formation of cerebral edema lead-
ing to a reduction of intracranial hypertension.
 In conclusion, our current results suggest that MMP-9 
contributes to brain edema formation after experimental 
SAH and might represent a promising pharmacological 
target for the treatment of SAH.
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